Biopharmas in Asia-Pacific raising money in public or private financings: Alebund.

Mountainfield Venture Partners and Chengdu, China-based Keymed Biosciences Co. Ltd have partnered to form San Diego-based Timberlyne Therapeutics, which will progress Keymed’s CD-38 monoclonal antibody globally excluding China.

Biopharmas raising money in public or private financings, including: A2, Amylyx, Calidi, Eli Lilly, Kardigan, Numab, Rhygaze.

Med-tech firms raising money in public or private financings, including: Caidya.

Normunity Inc. has closed a $75 million series B financing to support its pipeline of novel anticancer therapies targeting untapped drug mechanisms. Proceeds from the financing will be used to advance Normunity’s lead program, NRM-823, a first-in-class T-cell engager.

Windward Bio AG was established with plans to both license a drug and establish wet labs to create an internal pipeline of drug candidates. SR One, Omega Funds, RTW Investments, Qiming Venture Partners, Quan Capital and Pivotal Bioventure Partners funded the Basel, Switzerland-based company’s $200 million series A financing round.

Biopharmas raising money in public or private financings, including: A2 Biotherapeutics, Anacardio, Calidi, Light Horse, Rheumagen, Thetis.

Med-tech firms raising money in public or private financings, including: Microbot Medical, Saluda Medical, Vensana Capital.